Keytruda Receives First Oncology Approval Based on Tumor Genetics, not Organ Site

Drug Industry Daily
A A
In a first, the FDA granted an indication to a cancer immunotherapy based on a tumor’s genetic makeup, regardless of disease site or tissue.

To View This Article:

Login

Subscribe To Drug Industry Daily